Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers

Transplantation

Volumn 97, Issue 3, 2014, Pages 310-315

  Opelz, Gerhard ^a   Döhler, Bernd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ACEI; Antihypertensive drugs; ARB; Cardiovascular death; Kidney transplant

Indexed keywords

ADOLESCENT; ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; FEMALE; GRAFT SURVIVAL; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; RISK FACTORS; SOFTWARE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894206310     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000437672.78716.28     Document Type: Article

References (22)

1. USRDS Annual Data Report 2012. Available at http://www.usrds.org/adr. aspx. Accessed May 20, 2013.
2. Opelz G, Döhler B. Association of HLA mismatch with death with a functioning graft after kidney transplantation: a collaborative transplant study report. Am J Transplant 2012; 12: 3031.
3. Pilmore H, Dent H, Chang S, et al. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010; 89: 851.
4. Carpenter MA, Weir MR, Adey DB, et al. Inadequacy of cardiovascular risk factor management in chronic kidney transplantationVevidence from the FAVORIT study. Clin Transplant 2012; 26: E438.
5. Cosio FG, Hickson LJ, Griffin MD, et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant 2008; 8: 593.
6. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415.
7. Vanrenterghem Y. Anemia after kidney transplantation. Transplantation 2009; 87: 1265.
8. Afzali B, Al-Khoury S, Shah N, et al. Anemia after renal transplantation. Am J Kidney Dis 2006; 48: 519.
9. Krüger B, Walberer A, Debler J, et al. Is inflammation prior to renal transplantation predictive for cardiovascular and renal outcomes? Atherosclerosis 2010; 210: 637.
10. Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009; 69: 2227.
11. Gaston RS, Kasiske BL, Fieberg AM, et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9: 1811.
12. Hoogwerf BJ. ReninYangiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010; 105(1 Suppl): 30A.
13. Chatzikyrkou C, Menne J, Gwinner W, et al. Pathogenesis and management of hypertension after kidney transplantation. J Hypertens 2011; 29: 2283.
14. Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7: 2350.
15. Cross NB, Webster AC, Masson P, et al. Antihypertensive treatment for kidney transplant recipients. Cochrane Database Syst Rev 2009; 3: CD003598.
16. Cruzado JM, Rico J, Grinyó JM. The rennin angiotensin system blockade in kidney transplantation: pros and cons. Transplant Int 2008; 21: 304.
17. Salzberg DJ. Is RAS blockade routinely indicated in hypertensive kidney transplant patients? Curr Hypertens Rep 2007; 9: 422.
18. Jennings DL, Taber DJ. Use of reninYangiotensinYaldosterone system inhibitors within the first eight to twelve weeks after renal transplantation. Ann Pharmacother 2008; 42: 116.
19. Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257.
20. Paoloetti E, Bellino D, Marsano L, et al. Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial. Transplantation 2013; 95: 889.
21. Ibrahim HN, Jackson S, Connaire J, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol 2013; 24: 320.
22. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889.